1. Home
  2. FATE vs PFO Comparison

FATE vs PFO Comparison

Compare FATE & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATE
  • PFO
  • Stock Information
  • Founded
  • FATE 2007
  • PFO 1991
  • Country
  • FATE United States
  • PFO United States
  • Employees
  • FATE N/A
  • PFO N/A
  • Industry
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • PFO Finance Companies
  • Sector
  • FATE Health Care
  • PFO Finance
  • Exchange
  • FATE Nasdaq
  • PFO Nasdaq
  • Market Cap
  • FATE 116.5M
  • PFO 127.2M
  • IPO Year
  • FATE 2013
  • PFO N/A
  • Fundamental
  • Price
  • FATE $1.47
  • PFO $9.71
  • Analyst Decision
  • FATE Hold
  • PFO
  • Analyst Count
  • FATE 6
  • PFO 0
  • Target Price
  • FATE $3.30
  • PFO N/A
  • AVG Volume (30 Days)
  • FATE 3.1M
  • PFO 31.8K
  • Earning Date
  • FATE 11-11-2025
  • PFO 01-01-0001
  • Dividend Yield
  • FATE N/A
  • PFO 6.51%
  • EPS Growth
  • FATE N/A
  • PFO N/A
  • EPS
  • FATE N/A
  • PFO N/A
  • Revenue
  • FATE $8,470,000.00
  • PFO N/A
  • Revenue This Year
  • FATE N/A
  • PFO N/A
  • Revenue Next Year
  • FATE N/A
  • PFO N/A
  • P/E Ratio
  • FATE N/A
  • PFO N/A
  • Revenue Growth
  • FATE N/A
  • PFO N/A
  • 52 Week Low
  • FATE $0.66
  • PFO $6.90
  • 52 Week High
  • FATE $3.50
  • PFO $8.51
  • Technical
  • Relative Strength Index (RSI)
  • FATE 62.81
  • PFO 53.56
  • Support Level
  • FATE $1.30
  • PFO $9.66
  • Resistance Level
  • FATE $1.65
  • PFO $9.81
  • Average True Range (ATR)
  • FATE 0.17
  • PFO 0.10
  • MACD
  • FATE 0.02
  • PFO -0.02
  • Stochastic Oscillator
  • FATE 73.77
  • PFO 24.49

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.

Share on Social Networks: